Reversal of Radiotherapy Resistance of Ovarian Cancer Cell Strain CAOV3/R by Targeting lncRNA CRNDE-Reference-Cited by-同舟云学术

Reversal of Radiotherapy Resistance of Ovarian Cancer Cell Strain CAOV3/R by Targeting lncRNA CRNDE

Published:2021-09-08 Issue: Volume:2021 Page:1-6
ISSN:2040-2309
Container-title:Journal of Healthcare Engineering
language:en
Short-container-title:Journal of Healthcare Engineering

Author:

Yang Wencui¹,Li Xiaoning²^ORCID,Zhao Lin¹,Zhao Fengju¹

Affiliation:

1. Department of Radiotherapy, Gansu Tumor Hospital, 730050 Lanzhou, Gansu, China

2. Gynecologic Oncology Department, Gansu Tumor Hospital, 730050 Lanzhou, Gansu, China

Abstract

Radiotherapy resistance is one of the key factors of poor prognosis of ovarian cancer clinical treatment. The search for key targets of ovarian cancer radiotherapy resistance has become a high priority. Long noncoding RNA plays an important role in tumor development. However, the key lncRNA in ovarian cancer radiotherapy resistance is not identified. Our finding that lncRNA CRNDE is highly expressed in the radiotherapy resistance cell line CAOV3/R drew our attention. Therefore, in this study, we targeted lncRNA CRNDE to analyze whether it is a key factor of radiotherapy resistance in ovarian cancer. Ultimately, we found that silencing lncRNA CRNDE could reverse CAOV3/R radiotherapy resistance, which would be a boon to clinical treatment.

Funder

Research Institute of Medical Sciences hospital list of items in Gansu Province

Publisher

Hindawi Limited

Subject

Health Informatics,Biomedical Engineering,Surgery,Biotechnology

Link

http://downloads.hindawi.com/journals/jhe/2021/8556965.pdf

Reference20 articles.

1. SREBP2 contributes to cisplatin resistance in ovarian cancer cells

2. MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer

3. Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea